<p>Renalytix AI Plc (RENXF) 發佈了其第四季度財報。以下是 Renalytix AI Plc 向投資者提供的信息概述。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據驅動的洞察和您需要的研究工具，以自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
<p>Renalytix AI Plc 是一家在腎臟健康生物預後領域的先鋒公司，專注於通過其 FDA 批准的 KidneyIntelX 平台進行早期慢性腎病風險評估。該公司在 2025 財年報告了顯著增長，總收入增長了 30%，商業檢測量上升了 37%，這得益於戰略合作伙伴關係和 Medicare 對其 KidneyIntelX.dkd 測試的報銷。關鍵財務亮點包括行政費用大幅減少超過 40%，基礎 EBITDA 虧損減少 54%，同時成功籌集資金總額達到 1850 萬英鎊。Renalytix 還通過與 MVP Health Care 和 Tempus AI 等新合作伙伴關係擴大了市場影響力，增強了其分銷網絡並支持其增長戰略。展望未來，Renalytix 專注於進一步將其 KidneyIntelX 技術整合到電子病歷中，擴大其保險支付方覆蓋範圍，並追求國際市場機會，以繼續在腎病管理領域的增長和創新軌跡。</p>

RNLXY

RNLXD

<p>Renalytix AI Plc 在其 2025 財年報告了強勁的增長，收入增長 30%，商業測試量上升 37%。公司將行政費用減少了超過 40%，EBITDA 虧損減少了 54%。成功的資本籌集總額達到 1850 萬英鎊。戰略合作伙伴關係和醫療保險報銷促進了增長。未來計劃包括擴展 KidneyIntelX 技術整合、保險覆蓋和國際市場機會</p>

<p>Renalytix AI Plc ( (RENXF) ) has released its Q4 earnings. Here is a breakdown of the information Renalytix AI Plc presented to its investors.</p>
<div class="lb-trans"><p>Renalytix AI Plc (RENXF) 發佈了其第四季度財報。以下是 Renalytix AI Plc 向投資者提供的信息概述。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據驅動的洞察和您需要的研究工具，以自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
</div><p>Renalytix AI Plc is a pioneering company in the field of bioprognosis for kidney health, focusing on early-stage chronic kidney disease risk assessment through its FDA-approved KidneyIntelX platform. The company has reported significant growth in its 2025 financial year, with a 30% increase in total revenues and a 37% rise in commercial testing volumes, driven by strategic partnerships and Medicare reimbursement for its KidneyIntelX.dkd test. Key financial highlights include a substantial reduction in administrative expenses by over 40% and a 54% decrease in underlying EBITDA loss, alongside successful capital raises totaling £18.5 million. Renalytix has also expanded its market presence with new partnerships, such as those with MVP Health Care and Tempus AI, enhancing its distribution network and supporting its growth strategy. Looking ahead, Renalytix is focused on further integrating its KidneyIntelX technology into electronic medical records, expanding its insurance payor coverage, and pursuing international market opportunities to continue its trajectory of growth and innovation in kidney disease management.</p>
<div class="lb-trans"><p>Renalytix AI Plc 是一家在腎臟健康生物預後領域的先鋒公司，專注於通過其 FDA 批准的 KidneyIntelX 平台進行早期慢性腎病風險評估。該公司在 2025 財年報告了顯著增長，總收入增長了 30%，商業檢測量上升了 37%，這得益於戰略合作伙伴關係和 Medicare 對其 KidneyIntelX.dkd 測試的報銷。關鍵財務亮點包括行政費用大幅減少超過 40%，基礎 EBITDA 虧損減少 54%，同時成功籌集資金總額達到 1850 萬英鎊。Renalytix 還通過與 MVP Health Care 和 Tempus AI 等新合作伙伴關係擴大了市場影響力，增強了其分銷網絡並支持其增長戰略。展望未來，Renalytix 專注於進一步將其 KidneyIntelX 技術整合到電子病歷中，擴大其保險支付方覆蓋範圍，並追求國際市場機會，以繼續在腎病管理領域的增長和創新軌跡。</p>
</div>

Renalytix AI 報告顯示強勁增長和戰略擴張